Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mds284PMID 22967996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes

  2011cited by this paper
• Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

  2011cited by this paper
• A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.

  2011cited by this paper
• Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.

  2011cited by this paper
• Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.

  2011cited by this paper
• Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

  2010cited by this paper
• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects

  2010cited by this paper
• The cardiac safety of trastuzumab in the treatment of breast cancer

  2010cited by this paper
• Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors.

  2009cited by this paper
• Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study.

  2009cited by this paper
• Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.

  2009cited by this paper
• Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

  2009cited by this paper
• A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

  2008cited by this paper
• A Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines

  2008cited by this paper
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

  2008cited by this paper
• Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

  2008cited by this paper
• Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

  2007cited by this paper
• Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

  2007cited by this paper
• A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.

  2007cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

  2006cited by this paper
• A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.

  2006cited by this paper
• Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

  2005cited by this paper
• Antitumor activity of HER-2 inhibitors.

  2005cited by this paper
• Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Combination of trastuzumab and vinorelbine in metastatic breast cancer.

  2003cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Clinical Pharmacokinetics of Vinorelbine

  1996cited by this paper
• The clinical pharmacokinetics of vinorelbine (Navelbine).

  1994cited by this paper
• Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.

  1994cited by this paper
• Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

  1994cited by this paper
• Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy.

  1994cited by this paper
• Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

  1993cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Her2 Breast Cancer Therapies: a Review in Order To

  year unknowncited by this paper

• Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer.

  2025cites this paper
• Trans-activating mutations of the pseudokinase ERBB3

  2024cites this paper
• Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications.

  2024cites this paper
• The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.

  2023cites this paper
• Neratinib for HER2-positive breast cancer with an overlooked option

  2023cites this paper
• Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review

  2023cites this paper
• The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer

  2023cites this paper
• Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

  2023cites this paper
• Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids

  2023cites this paper
• Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report.

  2022cites this paper
• Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital

  2022cites this paper
• Thoughts on therapy strategy in the era of “after anti-HER2 TKI” in CSCO BC Guidelines 2022

  2022influential citation
• Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

  2022cites this paper
• CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers

  2022cites this paper
• Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

  2021cites this paper
• Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study

  2021cites this paper
• Targeted Therapies in Older Adults With Solid Tumors.

  2021cites this paper
• Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

  2021cites this paper
• Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis

  2021cites this paper
• Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.

  2021cites this paper
• Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

  2021cites this paper
• Intracellular Signaling

  2020cites this paper
• Immunophenotyping of HER4/YAP axis in breast cancer brain metastasis

  2020cites this paper
• A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine

  2020cites this paper
• Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer

  2020cites this paper
• Genomics of gynaecological carcinosarcomas and future treatment options.

  2020cites this paper
• Novel HER2–targeted therapies for HER2–positive metastatic breast cancer

  2020cites this paper
• Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia.

  2019cites this paper
• Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

  2019cites this paper
• Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Neratinib in adjuvant treatment of patients with HER2-positive breast cancer — less is more?

  2019cites this paper
• Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.

  2019cites this paper
• Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.

  2019cites this paper
• Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer

  2019cites this paper
• Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2019cites this paper
• Pharmacotherapeutic options for patients with refractory breast cancer

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Neratinib in HER2-Positive Breast Cancer Patients

  2019cites this paper
• Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

  2019cites this paper
• Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

  2019cites this paper
• Targeted therapeutic options and future perspectives for HER2-positive breast cancer

  2019cites this paper
• Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects

  2019cites this paper
• Adjuvant Therapy for HER2-Positive Early-Stage Breast Cancer

  2018cites this paper
• Metastatic and triple-negative breast cancer: challenges and treatment options

  2018cites this paper
• Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives

  2018cites this paper
• Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect.

  2018cites this paper
• Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

  2018cites this paper
• Fatigue with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials

  2018cites this paper
• Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

  2018cites this paper
• Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer

  2018cites this paper
• Neratinib for the treatment of HER2-positive early stage breast cancer

  2017cites this paper
• Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis

  2017cites this paper
• HER 2-Directed Therapy for Metastatic Breast Cancer

  2017cites this paper
• Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

  2017cites this paper
• The role of neratinib in HER2-driven breast cancer.

  2017cites this paper
• Breast cancer treatment-induced cardiotoxicity

  2017cites this paper
• LC–MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma

  2017cites this paper
• HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers

  2017cites this paper
• Anti-HER2 Therapies in the Adjuvant and Advanced Disease Settings

  2017cites this paper
• Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4

  2017cites this paper
• Neratinib: First Global Approval

  2017cites this paper
• Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer

  2016cites this paper
• Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

  2016cites this paper
• Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

  2016cites this paper
• Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

  2016cites this paper
• The role of PI3K and ERBB family gene mutations and other abnormalities in resistance to HER2-targeted therapies in HER2-positive breast cancer

  2016cites this paper
• Neratinib for the treatment of breast cancer

  2016cites this paper
• Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

  2016cites this paper
• Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients

  2016cites this paper
• NANOTECHNOLOGY APPROACH FOR TARGETED TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

  2016cites this paper
• Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

  2016cites this paper
• Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer

  2016cites this paper
• Resistance to Targeted Therapies in Breast Cancer.

  2016cites this paper
• Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.

  2016cites this paper
• Profile of neratinib and its potential in the treatment of breast cancer

  2015cites this paper
• Management of patients with HER2‐positive metastatic breast cancer: Is there an optimal sequence of HER2‐directed approaches?

  2015cites this paper
• Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

  2015cites this paper
• Targeting Receptor Tyrosine Kinases in Cancer

  2015cites this paper
• University of Birmingham Profile of neratinib and its potential in the treatment of breast cancer

  2015cites this paper
• HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

  2015cites this paper
• Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease

  2015cites this paper
• Effective Management and Prevention of Neratinib-Induced Diarrhea

  2015cites this paper
• Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

  2015cites this paper
• Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

  2015cites this paper
• Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

  2015cites this paper
• New protein kinase inhibitors in breast cancer: afatinib and neratinib

  2014cites this paper
• Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade

  2014cites this paper
• Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models

  2014cites this paper
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Treatment of HER2-positive breast cancer.

  2014cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.

  2014cites this paper
• Time for more optimism in metastatic breast cancer?

  2014cites this paper
• Emerging EGFR antagonists for breast cancer

  2014cites this paper
• Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

  2014cites this paper
• Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

  2014cites this paper
• Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.

  2014cites this paper